Search Results - "Sati, Hamdi"

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial by Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Montes, Yolanda Gonzalez, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf Henrik, Fenk, Roland, Demarquette, Hélène, Sati, Hamdi, Vorog, Alexander, Labotka, Richard, Du, Jichang, Darif, Mohamed, Kumar, Shaji

“…Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age,…”
Get full text

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma by Gordon, Sharon, Helfrich, Miep H., Sati, Hamdi I. A., Greaves, Michael, Ralston, Stuart H., Culligan, Dominic J., Soutar, Richard L., Rogers, Michael J.

“…Anti‐resorptive bisphosphonates, such as pamidronate, are an effective treatment for osteolytic disease and hypercalcaemia in patients with multiple myeloma,…”
Get full text

Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma by Sati, Hamdi I. A., Greaves, Mike, Apperley, Jane F., Russell, R. Graham G., Croucher, Peter I.

“…Interleukin‐1β (IL‐1β) and tumour necrosis factor‐α (TNF‐α) are potent bone resorbing cytokines that may contribute to the development of the osteolytic bone…”
Get full text

Interleukin‐6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance by Sati, Hamdi I. A., Apperley, Jane F., Greaves, Mike, Lawry, John, Gooding, Roger, Russell, R. Graham G., Croucher, Peter I.

“…Interleukin‐6 (IL‐6) is an important growth factor for human myeloma cells in vitro and in vivo. However, the identity of the cells producing IL‐6 in vivo in…”
Get full text

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD) by Cook, Gordon, Ashcroft, A J, Senior, Ethan R, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, James D., Snowden, John, Drayson, Mark, de Tute, Ruth M, Owen, Roger, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David Allan, Parrish, Christopher

“…Introduction: sASCT in multiple myeloma (MM) induces superior durability of response over non-transplant consolidation 1. Currently there is no prospective…”
Get full text

OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma by Parrish, Christopher, Welsh, Alexandra, Ashcroft, John, Olivier, Catherine, Hockaday, Anna, Cavenagh, Jamie, Snowden, John, Drayson, Mark, De Tute, Ruth, Owen, Roger, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Richards, Jeanine, Cook, Mark, Roberts, Lesley, Cairns, David, Cook, Gordon

Get full text

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial by Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Yolanda, Gonzalez montes, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf-Henrik, Fenk, Roland, Sati, Hamdi, Vorog, Alexander, Labotka, Richard J., Du, Jichang, Darif, Mohamed, Kumar, Shaji

“…Abstract only 8020 Background: MM patients (pts) often receive several lines of therapy with multiple drug combinations and, as lenalidomide (R)-containing…”
Get full text

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial by Cook, Gordon, Ashcroft, A John, Senior, Ethan, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, Jamie D, Snowden, John A, Drayson, Mark T, de Tute, Ruth, Roberts, Lesley, Owen, Roger G, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David A, Parrish, Christopher

“…The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple…”
Get full text

Expression of interleukin-1(beta) and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma by Sati, Hamdi I A, Greaves, Mike, Apperley, Jane F, Russell, R Graham G, Croucher, Peter I

Get full text